Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

  • Quoted phrase not found.
1.

Direct Drug Susceptibility Testing of Mycobacterium tuberculosis using the proportional method: a Multicenter Study.

Amini S, Hoffner S, Allahyar Torkaman M, Hamzehloo G, Nasiri MJ, Salehi M, Kashkooli GS, Shahraki M, Mohsenpoor M, Soleimanpour S, Mir R.

J Glob Antimicrob Resist. 2019 Jan 7. pii: S2213-7165(19)30004-9. doi: 10.1016/j.jgar.2018.12.022. [Epub ahead of print]

PMID:
30630107
2.

A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs.

Belur Nagaraj A, Joseph P, Ponting E, Fedorov Y, Singh S, Cole A, Lee W, Yoon E, Baccarini A, Scacheri P, Buckanovich R, Adams DJ, Drapkin R, Brown BD, DiFeo A.

Stem Cell Reports. 2019 Jan 8;12(1):122-134. doi: 10.1016/j.stemcr.2018.12.002.

3.

LncRNA MIAT Facilitates Osteosarcoma Progression by Regulating miR-128-3p/VEGFC Axis.

Zhang C, Xie L, Liang H, Cui Y.

IUBMB Life. 2019 Jan 10. doi: 10.1002/iub.2001. [Epub ahead of print]

PMID:
30629798
4.

Identification of Candidate miRNA Biomarkers for Glaucoma.

Hindle AG, Thoonen R, Jasien JV, Grange RMH, Amin K, Wise J, Ozaki M, Ritch R, Malhotra R, Buys ES.

Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):134-146. doi: 10.1167/iovs.18-24878.

5.

Bioinformatic analysis of long-lasting transcriptional and translational changes in the basolateral amygdala following acute stress.

Sillivan SE, Jones ME, Jamieson S, Rumbaugh G, Miller CA.

PLoS One. 2019 Jan 10;14(1):e0209846. doi: 10.1371/journal.pone.0209846. eCollection 2019.

6.

NOTCH1 Gene MicroRNA Target Variation and Ventricular Septal Defect Risk.

Ji L, Hou H, Zhu K, Liu X, Liu Y, Wang Q, Li J, Liu H, Zhang Q, Lv J, Alexander R, Wang W, Li D.

OMICS. 2019 Jan;23(1):28-35. doi: 10.1089/omi.2018.0171.

PMID:
30629480
7.

Proteomics analysis reveals that structural proteins of the virion core and involved in gene expression are the main source for HLA class II ligands in vaccinia virus-infected cells.

Lorente E, Martín-Galiano AJ, Barnea E, Barriga A, Palomo C, García-Arriaza J, Mir C, Lauzurica P, Esteban M, Admon A, Lopez D.

J Proteome Res. 2019 Jan 10. doi: 10.1021/acs.jproteome.8b00595. [Epub ahead of print]

PMID:
30629447
8.

Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy.

Costantino S, Akhmedov A, Melina G, Mohammed SA, Othman A, Ambrosini S, Wijnen WJ, Sada L, Ciavarella GM, Liberale L, Tanner FC, Matter CM, Hornemann T, Volpe M, Mechta-Grigoriou F, Camici GG, Sinatra R, Lüscher TF, Paneni F.

Eur Heart J. 2019 Jan 9. doi: 10.1093/eurheartj/ehy903. [Epub ahead of print]

PMID:
30629164
9.

A Study on the Correlations of the miR-31 Expression with the Pathogenesis and Prognosis of Head and Neck Squamous Cell Carcinoma.

Qiang H, Zhan X, Wang W, Cheng Z, Ma S, Jiang C.

Cancer Biother Radiopharm. 2019 Jan 10. doi: 10.1089/cbr.2018.2621. [Epub ahead of print]

PMID:
30628842
10.

MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review).

Hu M, Zhu S, Xiong S, Xue X, Zhou X.

Oncol Rep. 2019 Jan 10. doi: 10.3892/or.2019.6962. [Epub ahead of print]

PMID:
30628706
11.

MicroRNA‑758 inhibits tumorous behavior in tongue squamous cell carcinoma by directly targeting metadherin.

Zhang Y, Zhao F.

Mol Med Rep. 2019 Jan 2. doi: 10.3892/mmr.2019.9805. [Epub ahead of print]

PMID:
30628702
12.

miR‑625‑5p suppresses inflammatory responses by targeting AKT2 in human bronchial epithelial cells.

Qian FH, Deng X, Zhuang QX, Wei B, Zheng DD.

Mol Med Rep. 2019 Jan 3. doi: 10.3892/mmr.2019.9817. [Epub ahead of print]

PMID:
30628701
13.

microRNA‑577 inhibits cell proliferation and invasion in non‑small cell lung cancer by directly targeting homeobox A1.

Men L, Nie D, Nie H.

Mol Med Rep. 2019 Jan 2. doi: 10.3892/mmr.2019.9804. [Epub ahead of print]

PMID:
30628697
14.

MicroRNA‑192 acts as a tumor suppressor in colon cancer and simvastatin activates miR‑192 to inhibit cancer cell growth.

Zheng XF, Liu KX, Wang XM, Zhang R, Li X.

Mol Med Rep. 2019 Jan 2. doi: 10.3892/mmr.2019.9808. [Epub ahead of print]

PMID:
30628692
15.

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1.

Liu H, Guo J, Chai H, Meng X.

Mol Med Rep. 2019 Jan 4. doi: 10.3892/mmr.2019.9826. [Epub ahead of print]

PMID:
30628685
16.

MicroRNA‑18b acts as an oncogene in gastric cancer by directly targeting Kruppel‑like factor 6.

Luo D, Chen J, Huang S, Xu J, Song X, Yu P.

Mol Med Rep. 2019 Jan 8. doi: 10.3892/mmr.2019.9830. [Epub ahead of print]

PMID:
30628682
17.

miRNA-20b inhibits cerebral ischemia-induced inflammation through targeting NLRP3.

Zhao J, Wang H, Dong L, Sun S, Li L.

Int J Mol Med. 2018 Dec 31. doi: 10.3892/ijmm.2018.4043. [Epub ahead of print]

PMID:
30628668
18.

MicroRNA‑223 promotes osteoblast differentiation of MC3T3‑E1 cells by targeting histone deacetylase 2.

Chen J, He G, Wang Y, Cai D.

Int J Mol Med. 2018 Dec 31. doi: 10.3892/ijmm.2018.4042. [Epub ahead of print]

PMID:
30628667
19.

miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells.

Tang H, Lv W, Sun W, Bi Q, Hao Y.

Int J Mol Med. 2018 Dec 31. doi: 10.3892/ijmm.2018.4041. [Epub ahead of print]

PMID:
30628663
20.

MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.

Funamizu N, Lacy CR, Kamada M, Yanaga K, Manome Y.

Int J Oncol. 2019 Jan 7. doi: 10.3892/ijo.2019.4676. [Epub ahead of print]

PMID:
30628651

Supplemental Content

Loading ...
Support Center